Recent advisory opinion offers insight on how healthcare providers may want to structure arrangements involving online directories.
National Lab Reporter
Keeps You Up-to-Date on Federal & State Laws, Regulations, New Legislation, and Court Cases that Affect Your Diagnostic Lab or Pathology Practice
Subscribe today for access to
Articles and Reports
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
The proposed PFS rule also includes other changes that will affect physician, lab, and other reimbursements in 2024 and beyond.
Recently proposed rule seems too stringent to reduce the lag between FDA approval and Medicare coverage.
Recently released Centers for Medicare and Medicaid Services guidance shares when CLIA regulations apply to international labs.
Federal lawmakers have renewed efforts to pass legislation ensuring Medicare coverage of multi-cancer early detection (MCED) tests.
Ruling could spell good news for labs and other healthcare providers targeted by whistleblowers in False Claims Act qui tam lawsuits.
False billing of urine drug tests (UDTs) continues to be a focus for enforcement agencies in 2023, here’s how to avoid compliance issues.
Here’s what to know about the new codes that CMS recently added to the national HCPCS table as well as which ones were removed.
These three lab testing areas were the main sources of fraud and abuse revealed in the OIG’s latest Semi-Annual Report to Congress.
Congress is renewing its previous efforts to make Medicare reimbursement of pharmacy testing permanent—here’s what that could mean for labs.
Compliance Alert: OIG Sounds the Alarm on Medicare Overpayments for Physician Services Provided to Inpatients
According to a recent report, Medicare overpaid for such services over a two-year period between 2019 and 2020.
Current genetic testing enforcement trends and what you can do to minimize the liability risks of your lab.